# Anthrax > The content on this page is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. If you have health concerns, consult a qualified healthcare professional. Medova is not a medical service provider. Source: https://medova.health/en/knowledge/diseases/anthrax · Language: en ## Overview Serious bacterial disease caused by Bacillus anthracis spores, occurring as cutaneous, inhalation, or gastrointestinal forms. ## Medical Information - ICD-10: A22 - ICD-11: 1C17 - Causative Agent: bacteria - Severity: Critical - Incubation Period: 1–60 days - Mortality Rate: 0.2% - Vaccine available: Yes ## Overview Anthrax is a serious infectious disease caused by Bacillus anthracis, a spore-forming bacterium found in soil. It occurs in three main clinical forms: cutaneous (skin), inhalation (lung), and gastrointestinal. Vaccination is available for high-risk groups. ## Overview Anthrax is primarily a disease of herbivorous animals (cattle, sheep, goats) that can be transmitted to humans through contact with infected animals or contaminated animal products. The bacterium forms highly resilient spores that can survive in the environment for decades.\\n\\nHuman cases are relatively rare and occur mainly in agricultural and industrial settings in endemic areas. Cutaneous anthrax accounts for about 95% of human cases. Anthrax is classified as a Category A bioterrorism agent due to the potential weaponization of spores. ## Emergency Signs - rapidly expanding skin lesion with severe surrounding swelling\\n- sudden onset of breathing difficulty or chest tightness after possible spore exposure\\n- signs of sepsis: high fever, rapid heart rate, confusion, very low blood pressure\\n- bloody vomiting or severe bloody diarrhea with abdominal distension ## Detailed Symptoms Symptoms depend on the form of infection.\\n\\n**Cutaneous (95% of cases):** Painless papule that progresses to a vesicle, then to a characteristic black eschar (scab) with surrounding edema. Fever, malaise, and regional lymph node swelling.\\n\\n**Inhalation:** Initial flu-like phase (fever, malaise, nonproductive cough) followed by abrupt deterioration with severe breathing difficulty, chest pain, and shock.\\n\\n**Gastrointestinal:** Nausea, vomiting, fever progressing to severe abdominal pain, bloody diarrhea, and fluid accumulation in the abdomen. ## Course of Disease Cutaneous: incubation period 1–12 days; lesion evolves over 7–10 days and heals in 2–6 weeks with treatment. Inhalation: incubation 1–60 days (typically 1–5 days); initial prodrome lasting 2–5 days followed by rapid fulminant phase with respiratory failure. Gastrointestinal: incubation 1–7 days with potential for rapid progression. ## Diagnosis Diagnosis is based on clinical suspicion, exposure history, and characteristic findings such as the black eschar in cutaneous anthrax. Confirmed by laboratory culture of blood, lesion swabs, or other specimens. Rapid molecular testing (PCR) and antigen detection are available. Any suspected case must be reported to public health authorities immediately. ## Treatment All forms require antibiotic therapy prescribed by a physician. Treatment is most effective when started early. Cutaneous anthrax (uncomplicated) is treated with oral antibiotics for 7–10 days. Systemic and inhalation anthrax require combination intravenous antibiotics for extended duration. Antitoxin therapy is available for inhalation anthrax. Post-exposure prophylaxis with antibiotics may be given after confirmed exposure. Always seek immediate medical care if anthrax is suspected. ## Prevention Details - avoid direct contact with potentially infected animals and unprocessed animal products\\n- occupational hygiene: use protective clothing and decontamination procedures\\n- vaccination (anthrax vaccine adsorbed) is available for high-risk occupational groups and military personnel\\n- proper handling and disposal of animal carcasses in endemic areas\\n- post-exposure prophylaxis with antibiotics if exposure is confirmed ## Travel Advice - anthrax is not a typical travel risk for most travelers\\n- avoid contact with sick or dead animals in endemic areas\\n- do not purchase unprocessed animal hides, wool, or leather goods from informal markets\\n- seek immediate medical attention if a suspicious skin lesion develops after animal contact\\n- pre-exposure vaccination is only recommended for specific high-risk occupational groups ## How common is it? Anthrax occurs worldwide but is most common in agricultural regions of Central and South America, sub-Saharan Africa, Central and South Asia, and southern and eastern Europe. Human cases are relatively rare globally. Occupational exposure among farmers, veterinarians, and wool sorters remains the primary risk factor. Sporadic outbreaks occur after contact with infected livestock or contaminated animal products. ## Risk Factors - occupational exposure to animals or animal products (farmers, veterinarians, abattoir workers)\\n- handling untreated hides, wool, or bone meal from endemic areas\\n- travel to agricultural regions with known anthrax in livestock\\n- laboratory work with Bacillus anthracis\\n- potential bioterrorism exposure ## Complications Details Cutaneous anthrax may lead to secondary infection or sepsis if untreated. Inhalation anthrax frequently causes hemorrhagic inflammation of the chest cavity, fluid accumulation around the lungs, meningitis, and multiorgan failure. Gastrointestinal anthrax can result in intestinal perforation, massive hemorrhage, and septic shock. All systemic forms carry high mortality risk without prompt antibiotic treatment. ## Recovery & Outlook Prognosis varies greatly by clinical form. Cutaneous anthrax has less than 1% fatality with appropriate treatment. Inhalation anthrax carries approximately 45% fatality even with treatment and over 85% without. Gastrointestinal anthrax fatality ranges from 25% to 60%. Early diagnosis and prompt antibiotic therapy are critical for survival in all systemic forms. ## Available Vaccines - [Anthrax](https://medova.health/en/knowledge/vaccines/anthrax) ## Sources & content verification - Data sources: WHO Disease Factsheets 2024 + CDC Yellow Book 2024 + Heymann CDD 21st ed. - Generated by: AI - Review status: Awaiting medical review - Last updated: 2026-08-23 --- The content on this page is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. If you have health concerns, consult a qualified healthcare professional. Medova is not a medical service provider. [Full terms of use](https://medova.health/en/terms)